KRAS Multiplex Mutation Screening Kit
The Atila KRAS Multiplex Mutation Screening Kit identifies 61 possible mutation sites in a single well in a rapid and cost-effective manner, including KRAS exon 2, 3, and 4 mutation groups.
Each kit includes 100 tests.
CE-IVD Certified. Meets EU standards for safety and performance.
KRAS Multiplex Mutation Screening Kit
KRAS is one of the oncogenes with the highest mutation rate in human malignant tumors. KRAS is a driving factor for multiple cancer types, such as, lung cancer, colorectal cancer, pancreatic cancer, and other tumors with high mortality. KRAS mutations occur in approximately 25% of human cancers, and more than 90% of pancreatic and lung cancers.
Cancer is a genetic disease with uncontrolled growth of abnormal cells. Some types of cancer are frequently associated with specific genetic mutations. Those mutations provide the biomarkers that allow more specific cancer treatments, known as targeted therapy.
Targeted therapy is a newer type of cancer treatment that offers patients the opportunity to use a drug that has a greater effect on cancerous tissue, reducing many of the side effects associated with standard therapy. Therefore, it is a critical step towards targeted therapy by identifying the cancer mutations with a precise and sensitive method.
Features Include
Technical Specs
Workflow Overview for the KRAS Multiplex Mutation Screening Kit
This section is for demonstrative purposes only and may be incomplete or inaccurate. Always refer to the product instructions for precise guidelines and directions.
DNA Extraction
PCR Reaction Assembly
Digital PCR
